Linus Biotechnology

Executive Summary

Linus Biotechnology is a pioneering precision medicine company focused on decoding the exposome through hair analysis. Its proprietary platform, ClearStrand, creates a temporal map of molecular changes from a single strand of hair, capturing a record of environmental exposures and biological responses. The company's first commercial product, ClearStrand-ASD, is a diagnostic aid for Autism Spectrum Disorder (ASD) designed to enable earlier diagnosis and intervention. By analyzing hair biomarkers, LinusBio offers a non-invasive, objective tool that could transform ASD diagnosis, which currently relies on subjective behavioral assessments. The company's technology has the potential to extend to other conditions, such as neurodegenerative diseases and metabolic disorders, positioning it as a leader in exposome-based diagnostics. LinusBio is based in New York and has achieved regulatory approval for its initial product. With a strong intellectual property portfolio and growing clinical evidence, the company is well-positioned to disrupt the diagnostic market. Its platform's ability to integrate environmental exposures with biological responses offers unique value for drug development and patient monitoring. As the first commercial product launches, LinusBio is poised to capture a significant share of the ASD diagnostics market, estimated at over $1 billion globally. The company's next steps include scaling manufacturing, building commercial partnerships, and expanding its pipeline to additional indications, which could drive substantial growth and valuation increases.

Upcoming Catalysts (preview)

• Q2 2025Commercial launch of ClearStrand-ASD test90% success
• Q3 2025Strategic partnership with national reference laboratory65% success
• Q1 2026Initiation of clinical study for exposome biomarker in Alzheimer's disease40% success